Thanks to the support of our event sponsors and all who contributed by attending, donating and participating in the silent auction and raffle, we are thrilled to announce the Believe Ball raised $450,000 in its inaugural year!
Two weeks ago I received a message from parents who were at the CHOP Pediatric Intensive Care Unit. Their infant son Gregory was on the ventilator from the storm after receiving the T-cell treatment that cured Emily. We set up a call and they said that they just wanted to talk to someone who witnessed their child go through this brutal storm when the T-cells are battling the cancer.
On September 6-7, we had the pleasure of attending the 3rd Annual CAR-TCR Summit in Boston. In partnership with the CAR-TCR Summit, the Emily Whitehead Foundation hosted a silent auction for the conference attendees and raised a total $6,000!
This week marks a huge milestone for pediatric cancer research. The U.S. Food and Drug Administration (FDA) announced Wednesday that is has approved Novartis CAR-T cell therapy CTL019—now Kymriah—for pediatric patients with acute lymphoblastic leukemia (ALL)!
On August 11-12 UMI Performance, Inc. hosted their UMI Performance Cruise In & Autocross. Proceeds from the event's bake sale and t-shirt sale benefitted EWF, which Minnesota-based Viking Performance, Inc. then generously matched to bring the total raised to $2500!
On Wednesday, July 12 the FDA's Oncologic Drugs Advisory Committee convened at a meeting to discuss the pending approval of CAR-T cell therapy CTL019. Our co-founders were present at the meeting, and Tom Whitehead spoke.